In a report released yesterday, Judah Frommer from Morgan Stanley maintained a Buy rating on Bicara Therapeutics Inc., with a price target of $36.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Judah Frommer’s rating is based on the promising developments in Bicara Therapeutics’ ongoing clinical trials, particularly the FORTIFI-HN01 study. The study involves ficerafusp alfa combined with pembrolizumab in HPV-negative head and neck squamous cell carcinoma, showing potential for improved outcomes compared to standard treatments.
Frommer also highlights the anticipated data from various dosing regimens in the Phase 1b trials, which could further inform the optimal dosing strategy for future phases. Additionally, the company’s financial stability, with a cash runway extending into the first half of 2029, supports the Buy rating by providing a solid foundation for continued research and development efforts.
According to TipRanks, Frommer is an analyst with an average return of -7.3% and a 42.45% success rate. Frommer covers the Healthcare sector, focusing on stocks such as Galapagos, RegenXBio, and PTC Therapeutics.